SAN DIEGO and ST. PETERSBURG, Fla., June 21, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, and
MediNcrease Health Plans, LLC, a national provider network and
provider advocacy firm, announce an agreement making Biocept's
Target Selector™ liquid biopsy tests accessible through
MediNcrease's client base of regional and national health plans,
insurance companies, employers, municipalities, third-party
administrators, unions and other companies involved in the
management of medical claims.
"We are thrilled to welcome Biocept as our newest provider and
to make its specialized liquid biopsy diagnostic services
accessible to our MediNcrease partners," said Linda Plaster, Chief Executive Officer of
MediNcrease. "This exciting relationship affirms our
continued commitment to increasing the accessibility of
leading-edge diagnostic services to our partners by expanding our
comprehensive network of providers."
"We are pleased to become a provider for MediNcrease and its
clients," said Amy McNeal, Vice
President of Reimbursement Strategies at Biocept.
"MediNcrease offers innovative payment solutions that benefit
both the payer and provider communities. Our ability to
expand our services to groups such as MediNcrease is indicative of
the growing acceptance of liquid biopsy testing within the medical
community. With this agreement in place, more than 190
million consumers have access to our liquid biopsy services."
"Expanding the number of managed care agreements is among our
key strategic objectives as more cancer patients gain access to the
potential benefits of using liquid biopsies," said Biocept's
President and Chief Executive Officer Michael Nall. "Our Target Selector™ tests
can be complementary to tissue biopsy with the ability to increase
the chances of finding actionable biomarkers and rapidly qualify
more patients for targeted therapy, which can result in improved
patient outcomes."
About MediNcrease Health Plans
MediNcrease is a
uniquely positioned national provider network and provider advocacy
firm servicing the commercial health, workers' compensation and
auto medical markets. Its advanced provider network and
negotiation solutions not only help facilitate millions of dollars
in expedited payments to providers each year, but also provide
medical payers with dramatically improved savings and service over
traditional PPO networks. The result is a 100% defensible and
transparent solution for both providers and payers. For more
information, please visit the company's website at
http://medincrease.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
leverages its proprietary liquid biopsy technology to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with cancer. Biocept's patented
Target Selector™ liquid biopsy technology platform captures and
analyzes tumor-associated molecular markers in both circulating
tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Biocept's Forward-Looking Statements Disclaimer
Statement
This news release contains forward-looking
statements that are based upon current expectations or beliefs, as
well as a number of assumptions about future events. Although
we believe that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are
reasonable, we can give no assurance that such expectations and
assumptions will prove to be correct. Forward-looking statements
are generally identifiable by the use of words like "may," "will,"
"should," "could," "expect," "anticipate," "estimate," "believe,"
"intend" or "project," or the negative of these words or other
variations on these words or comparable terminology. To the
extent that statements in this news release are not strictly
historical, including, without limitation, statements as to our
ability to improve the outcomes of cancer patients, the utility and
effectiveness of our intellectual property protections, the
financial impact of new contracts, and our ability to increase the
number of products or services provided or the value of the
Company, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such
risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
news release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC at www.sec.gov
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-and-medincrease-health-plans-announce-provider-agreement-expanding-access-to-liquid-biopsy-testing-300477165.html
SOURCE Biocept, Inc.